Your browser doesn't support javascript.
An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors.
Trezza, Alfonso; Iovinelli, Daniele; Santucci, Annalisa; Prischi, Filippo; Spiga, Ottavia.
  • Trezza A; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100, Siena, Italy.
  • Iovinelli D; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100, Siena, Italy.
  • Santucci A; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100, Siena, Italy.
  • Prischi F; School of Life Sciences, University of Essex, Colchester, CO4 3SQ, UK. fprischi@essex.ac.uk.
  • Spiga O; Department of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100, Siena, Italy. ottavia.spiga@unisi.it.
Sci Rep ; 10(1): 13866, 2020 08 17.
Article in English | MEDLINE | ID: covidwho-720849
ABSTRACT
The Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The virus has rapidly spread in humans, causing the ongoing Coronavirus pandemic. Recent studies have shown that, similarly to SARS-CoV, SARS-CoV-2 utilises the Spike glycoprotein on the envelope to recognise and bind the human receptor ACE2. This event initiates the fusion of viral and host cell membranes and then the viral entry into the host cell. Despite several ongoing clinical studies, there are currently no approved vaccines or drugs that specifically target SARS-CoV-2. Until an effective vaccine is available, repurposing FDA approved drugs could significantly shorten the time and reduce the cost compared to de novo drug discovery. In this study we attempted to overcome the limitation of in silico virtual screening by applying a robust in silico drug repurposing strategy. We combined and integrated docking simulations, with molecular dynamics (MD), Supervised MD (SuMD) and Steered MD (SMD) simulations to identify a Spike protein - ACE2 interaction inhibitor. Our data showed that Simeprevir and Lumacaftor bind the receptor-binding domain of the Spike protein with high affinity and prevent ACE2 interaction.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Computational Biology / Drug Discovery / Drug Repositioning / Betacoronavirus Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-70863-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Computational Biology / Drug Discovery / Drug Repositioning / Betacoronavirus Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2020 Document Type: Article Affiliation country: S41598-020-70863-9